About the Team

Amy Lee, President of CancerDx, is pursuing a bold plan to rethink the research, development, and commercialization of breakthrough medications that will help people with cancer and related blood disorders live longer and better lives.

Amy Lee began her career in life science as a sales representative in Germany for Bayer in 1985 and has since held positions of increasing seniority across a variety of business areas. She has spent the most of her career in oncology, where she is passionate about making a difference in people's lives. She was previously the President of Hematology of a biotech startup in Austria which focused on the development of targeted radioligand therapy and precision imaging products.

Our tests might determine whether a patient's tumor has a specific gene alteration or biomarker that the medicine is targeting. We help physicians and patients to leverage this information to assess whether or not the patient should receive the medication. Our tests can also be utilized to determine whether or not treatment will cause major adverse effects, as well as how well treatment is functioning. We target a wide spectrum of specific tumor mutations.